The new study shows that drugs commonly used for heartburn, stomach acid and boils can increase the risk of many deadly diseases, such as heart disease and stomach cancer.
Doctors often prescribe proton pump inhibitors (PPIs) for the treatment of gastrointestinal complaints involving excessive acid production.
Nexium, Aciphex, Zegerid, Dexilant, Prevacid, Prilosec and Protonix are just a few of the brands EPI has taken over the years.
More than 15 million people in the US receive IPPs according to the latest available statistics on prescriptions, and even more can receive IPOs for OTC services.
A new study published in BMJ shows that this drug can increase the risk of death in various chronic diseases.
Dr. Ziyad Al-Ali, medical assistant at the University of Washington Medical School, St. Louis, Missouri, is a senior researcher.
IPA is associated with a 17% higher risk of death
For the new study, Dr. med. Al-Ali and his colleagues looked at medical records from the US Department of Veterinary Affairs.
The researchers examined existing data from mid-2002 to mid-2004, a period in which 157,625 people in the group received prescriptions from their doctors for PPIs and 56,842 people received H2-blockers, another type of acid suppressor.
Scientists track participants – mostly men, whites and 65 years or more – clinically for up to a decade.
They used data to model statistics from clinical studies where participants randomly used PPIs or H2 blockers.
This allowed them to estimate that in the follow-up period, there would be 45.2 deaths per 1,000 people who received PML.
This discovery recognizes the cause of death and shows a connection with cardiovascular disease, gastric cancer and chronic kidney disease.
The model estimates cardiovascular mortality rates in the PPI group at 88.7 per 1000 and in the H2 blocker group at 73.3 per 1000.
These scientists saw 4.3 deaths per 1,000 people due to gastric cancer in the PPI group with 4.6 deaths from disease in the H2 blocker group in the model. The incidence of death from chronic kidney disease was 8.6 per 1,000 people in the PPI group and 4.4 in the H2-blocker group.
The risk of death also increases with the length of treatment, even if study participants have taken small doses of the drug.
Finally, research shows that more than half of people who use IPA do not need medical attention. “The most worrying thing about me is that people who work with PID but may not need it can be seriously injured,” Dr. Al-Ali. – Excessive use is not dangerous.
“IPA must be sold on the stock market, must have clear warnings about potential significant health risks, as well as clear warnings about the need to limit the useful life, usually up to 14 days,” continued the researchers. – People who believe that IPA samples need to be taken longer must consult their doctor.
“The introduction of science for months or years is uncertain, and we now have a clearer picture of the conditions associated with the use of long-term EPI,” Dr. Al-Ali.